News >

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC

Jason M. Broderick @jasoncology
Published: Monday, May 18, 2020

The FDA has approved single-agent atezolizumab (Tecentriq) as a first-line treatment for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression, as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Regarding safety, TRAEs occurred in 60.5% (arm A) and 85.2% (arm B) of patients.
FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer. Published May 18, 2020. Accessed May 18, 2020.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication